Drug Repurposing as an approach to control biofilm formation and encrustation of urinary catheters: Preclinical evidence and future challenges

Clicks: 1
ID: 317500
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #158 of 174 articles by views in Journal of applied microbiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 174 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Indwelling urethral catheters are the most widely used medical devices across the world, and catheter-associated urinary tract infections (CAUTIs) are the most common type of healthcare acquired infection. For many patients, urinary catheter blockage is a common and recurring problem, which can have considerable negative impact on patient health and well-being. Blockage primarily stems from the formation of crystalline bacterial biofilms on catheter surfaces, which can lead to upper urinary tract infection (UTI) and the onset of serious clinical complications. Potential solutions to this important clinical problem include the development of novel antibiofilm agents that can prevent formation of these communities on urinary catheters. However, traditional de novo methods of drug discovery are laborious, expensive, have long lead times and carry a high risk of failure in the clinical trial stages. One potential approach to mitigate this risk and cost, is the evaluation of pre-existing licensed drugs for those with useful antibiofilm or antimicrobial activity. Here we review current preclinical evidence for antibiofilm and antimicrobial activities in licensed drugs from a range of classes, such as urease inhibitors, Selective Serotonin Reuptake Inhibitors (SSRIs), phenothiazines, oncology therapeutics and non-steroidal anti-inflammatory drugs (NSAIDs). In doing so, we consider the application of the repurposing approach to control CAUTI and catheter blockage, and identify key challenges and opportunities related to delivery of repurposed drugs to the catheterised urinary tract.
Reference Key
openalex_W7164929508 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Anthony J. Slate, Catherine R E Lawler, Ocean E Clarke, Brian V. Jones
Journal Journal of applied microbiology
Year 2026
DOI
10.1093/jambio/lxag139
URL
https://doi.org/10.1093/jambio/lxag139
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.